175 related articles for article (PubMed ID: 34808632)
21. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
22. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease.
Scharnetzki D; Stappers F; Lenders M; Brand E
Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778
[TBL] [Abstract][Full Text] [Related]
23. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
24. Fabry disease: A fundamental genetic modifier of cardiac function.
Tadevosyan A
Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
[TBL] [Abstract][Full Text] [Related]
25. Complete Atrioventricular Block After Kidney Transplantation in a Patient With Fabry Disease Receiving Enzyme Replacement Therapy: A Case Report.
Shin DW; Cho JY; Bae EH; Ma SK; Kim SW; Kim CS
Transplant Proc; 2022; 54(1):107-111. PubMed ID: 34974891
[TBL] [Abstract][Full Text] [Related]
26. Concurrent fabry disease and immunoglobulin a nephropathy: a case report.
Zhou LN; Dong SS; Zhang SZ; Huang LW; Huang W
BMC Nephrol; 2023 Nov; 24(1):324. PubMed ID: 37914990
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease: diagnostic methods in nephrology practice.
Vujkovac B
Clin Nephrol; 2017 Supplement 1; 88(13):44-47. PubMed ID: 28601129
[TBL] [Abstract][Full Text] [Related]
28. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
30. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome.
Hossain MA; Yanagisawa H; Miyajima T; Wu C; Takamura A; Akiyama K; Itagaki R; Eto K; Iwamoto T; Yokoi T; Kurosawa K; Numabe H; Eto Y
Mol Genet Metab; 2017 Mar; 120(3):173-179. PubMed ID: 28087245
[TBL] [Abstract][Full Text] [Related]
31. De novo mutation in a male patient with Fabry disease: a case report.
Iemolo F; Pizzo F; Albeggiani G; Zizzo C; Colomba P; Scalia S; Bartolotta C; Duro G
BMC Res Notes; 2014 Jan; 7():11. PubMed ID: 24398019
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance.
Smid BE; Hollak CE; Poorthuis BJ; van den Bergh Weerman MA; Florquin S; Kok WE; Lekanne Deprez RH; Timmermans J; Linthorst GE
Clin Genet; 2015 Aug; 88(2):161-6. PubMed ID: 25040344
[TBL] [Abstract][Full Text] [Related]
33. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
35. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
36. Fabry disease in a patient with Turner syndrome.
Brouns R; Eyskens F; De Boeck K; Ceuterick-de Groote C; Van den Broeck M; Van Broeckhoven C; De Deyn PP
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S45-8. PubMed ID: 19343533
[TBL] [Abstract][Full Text] [Related]
37. Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.
Odani K; Okumi M; Honda K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():57-9. PubMed ID: 26971403
[TBL] [Abstract][Full Text] [Related]
38. Late-onset Fabry disease: the cardiac sequela.
Tremblay J; Kim S; Philbin E; Beers K; Lightle A; Belov D
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35680278
[TBL] [Abstract][Full Text] [Related]
39. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
[TBL] [Abstract][Full Text] [Related]
40. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
